Cephalexin and Hepatotoxicity
Yes, cephalexin can cause hepatotoxicity, though it is rare. The FDA drug label explicitly states that "transient hepatitis and cholestatic jaundice have been reported rarely" with cephalexin 1.
Clinical Evidence and Characteristics
The hepatotoxic potential of cephalexin is well-documented but uncommon:
Recent large-scale data from the Drug-Induced Liver Injury Network (2004-2022) identified only 4 cases of cephalexin-induced liver injury among 1,854 adjudicated DILI cases, representing less than 0.3% of all drug-induced liver injuries 2
Pattern of injury: Cephalexin typically causes a cholestatic or mixed hepatocellular-cholestatic pattern rather than pure hepatocellular injury 2, 3
Timing: Liver injury characteristically develops 1-4 weeks after starting therapy, often presenting after the antibiotic course has been completed 3, 4
Clinical presentation: Patients develop jaundice, elevated liver enzymes (particularly alkaline phosphatase and bilirubin), fatigue, and pruritus without hypersensitivity features like rash or fever 3, 4
Genetic Susceptibility
HLA-A*02:01 allele is significantly associated with cephalosporin-induced liver injury (odds ratio ~2.5-2.7), though this association is strongest with parenteral cephalosporins like cefazolin rather than oral cephalexin 2. This genetic marker may explain why only certain individuals develop hepatotoxicity.
Clinical Course and Management
The hepatotoxicity is self-limited in most cases:
- Complete resolution of liver function tests typically occurs within 4 weeks of discontinuing the drug 3
- Symptomatic treatment with cholestyramine can help manage pruritus during recovery 3
- No specific antidote exists; management is supportive with drug discontinuation 3, 4
Important Caveats
Do not confuse cephalexin with other cephalosporins: While all cephalosporins carry some hepatotoxicity risk, the incidence and patterns vary significantly. Ceftriaxone, for example, shows much higher rates of liver injury (19.4% in recent studies) compared to cephalexin 5. The general statement that "cephalosporins have very rarely been associated with hepatotoxicity" applies broadly, but individual agents differ substantially 6.
Monitoring Recommendations
Based on the FDA label and clinical evidence:
- Baseline assessment: Not routinely required for short courses in patients without pre-existing liver disease 1
- High-risk patients: Those with hepatic impairment or poor nutritional state warrant closer monitoring, as cephalosporins may be associated with decreased prothrombin activity 1
- Symptom surveillance: Educate patients to report jaundice, dark urine, light-colored stools, or severe fatigue developing during or up to 4 weeks after treatment 3, 4
- If hepatotoxicity occurs: Discontinue cephalexin immediately and avoid re-challenge, as the reaction can recur with repeat exposure 4
The bottom line: While cephalexin-induced hepatotoxicity is rare (affecting far less than 1% of users), it is a recognized adverse effect that clinicians must consider when patients develop liver test abnormalities during or shortly after cephalexin therapy.